Reduce motor symptoms with fasudil
- Trial ID
- NCT05931575
- Official Title
- Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD)
- Goal
- Reduce motor symptoms with fasudil
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- Technical University of Munich
- Study Type
- INTERVENTIONAL
- Enrollment
- 75 participants
- Conditions
- Idiopathic Parkinson´s Disease
- Interventions
- Fasudil hydrochloride, Placebo
Plain-Language Summary
The goal is to test whether blocking ROCK enzymes with fasudil is safe and can reduce neuroinflammation and support dopamine neuron health, which could ease motor symptoms and slow damage in Parkinson's. Fasudil is a ROCK inhibitor that alters cell scaffolding and inflammatory signals to help neurons survive and maintain axons, it is given in addition to usual Parkinson's drugs and does not replace levodopa. The trial is looking for people aged 30 to 80 with probable idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3, who are non‑fluctuating with no wearing-off or dyskinesia and have been on stable PD medication for at least 6 weeks. People with prior intracranial bleeding, uncontrolled blood pressure, serious liver or kidney problems, major psychiatric or cognitive disorders, or pregnancy are excluded.
Locations
- Technische Universität München, Klinikum rechts der Isar, Klinik und Poliklinik für Neurologie, Munich, Germany
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Fasudil hydrochloride. The goal is to test whether blocking ROCK enzymes with fasudil is safe and can reduce neuroinflammation and support dopamine neuron health, which could ease motor symptoms and slow damage in Parkinson's. Fasudil is a ROCK inhibitor that alters cell scaffolding and inflammatory signals to help neurons survive and maintain axons, it is given in addition to usual Parkinson's drugs and does not replace levodopa. The trial is looking for people aged 30 to 80 with probable idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3, who are non‑fluctuating with no wearing-off or dyskinesia and have been on stable PD medication for at least 6 weeks. People with prior intracranial bleeding, uncontrolled blood pressure, serious liver or kidney problems, major psychiatric or cognitive disorders, or pregnancy are excluded.
- Who can participate?
- Participants must be between 30 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 3 years and 1 month.